419 related articles for article (PubMed ID: 34884543)
1. The Role of the Immune System in IBD-Associated Colorectal Cancer: From Pro to Anti-Tumorigenic Mechanisms.
Frigerio S; Lartey DA; D'Haens GR; Grootjans J
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884543
[TBL] [Abstract][Full Text] [Related]
2. Role of Inflammation in the Development of Colorectal Cancer.
Muthusami S; Ramachandran IK; Babu KN; Krishnamoorthy S; Guruswamy A; Queimado L; Chaudhuri G; Ramachandran I
Endocr Metab Immune Disord Drug Targets; 2021; 21(1):77-90. PubMed ID: 32901590
[TBL] [Abstract][Full Text] [Related]
3. Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational Risks from Mechanisms to Medicines.
Porter RJ; Arends MJ; Churchhouse AMD; Din S
J Crohns Colitis; 2021 Dec; 15(12):2131-2141. PubMed ID: 34111282
[TBL] [Abstract][Full Text] [Related]
4. The Role of Mitochondria Dysfunction in Inflammatory Bowel Diseases and Colorectal Cancer.
Kłos P; Dabravolski SA
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769108
[TBL] [Abstract][Full Text] [Related]
5. Inflammation and colorectal cancer.
Kraus S; Arber N
Curr Opin Pharmacol; 2009 Aug; 9(4):405-10. PubMed ID: 19589728
[TBL] [Abstract][Full Text] [Related]
6. Comparative analysis of single-cell transcriptome reveals heterogeneity and commonality in the immune microenvironment of colorectal cancer and inflammatory bowel disease.
Lv H; Mu Y; Zhang C; Zhao M; Jiang P; Xiao S; Sun H; Wu N; Sun D; Jin Y
Front Immunol; 2024; 15():1356075. PubMed ID: 38529274
[TBL] [Abstract][Full Text] [Related]
7. NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.
Perera AP; Kunde D; Eri R
Curr Pharm Des; 2017; 23(16):2321-2327. PubMed ID: 28155620
[TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?
Dyson JK; Rutter MD
World J Gastroenterol; 2012 Aug; 18(29):3839-48. PubMed ID: 22876036
[TBL] [Abstract][Full Text] [Related]
9. Colorectal cancer in inflammatory bowel disease: the risk, pathogenesis, prevention and diagnosis.
Kim ER; Chang DK
World J Gastroenterol; 2014 Aug; 20(29):9872-81. PubMed ID: 25110418
[TBL] [Abstract][Full Text] [Related]
10. Immune System, Microbiota, and Microbial Metabolites: The Unresolved Triad in Colorectal Cancer Microenvironment.
Hanus M; Parada-Venegas D; Landskron G; Wielandt AM; Hurtado C; Alvarez K; Hermoso MA; López-Köstner F; De la Fuente M
Front Immunol; 2021; 12():612826. PubMed ID: 33841394
[TBL] [Abstract][Full Text] [Related]
11. Intestinal immunomodulation. Role of regulative peptides and promising pharmacological activities.
Motilva V; Talero E; Calvo JR; Villegas I; Alarcón-de-la-Lastra C; Sánchez-Fidalgo S
Curr Pharm Des; 2008; 14(1):71-95. PubMed ID: 18220820
[TBL] [Abstract][Full Text] [Related]
12. Morphological, immunohistochemical and molecular features of inflammatory bowel disease associated colorectal carcinoma and associated mucosal lesions - Single institution experience.
Kamarádová K; Vošmiková H; Rozkošová K; Ryška A; Tachecí I; Laco J
Pathol Res Pract; 2019 Apr; 215(4):730-737. PubMed ID: 30679085
[TBL] [Abstract][Full Text] [Related]
13. Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk?
Breynaert C; Vermeire S; Rutgeerts P; Van Assche G
Acta Gastroenterol Belg; 2008; 71(4):367-72. PubMed ID: 19317276
[TBL] [Abstract][Full Text] [Related]
14. Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment.
Axelrad JE; Lichtiger S; Yajnik V
World J Gastroenterol; 2016 May; 22(20):4794-801. PubMed ID: 27239106
[TBL] [Abstract][Full Text] [Related]
15. Prevention of cancer in IBD - a balancing act.
Mill J; Lawrance IC
Minerva Gastroenterol Dietol; 2013 Sep; 59(3):261-72. PubMed ID: 23867946
[TBL] [Abstract][Full Text] [Related]
16. The struggle within: microbial influences on colorectal cancer.
Arthur JC; Jobin C
Inflamm Bowel Dis; 2011 Jan; 17(1):396-409. PubMed ID: 20848537
[TBL] [Abstract][Full Text] [Related]
17. Malignancies in Inflammatory Bowel Disease.
Greuter T; Vavricka S; König AO; Beaugerie L; Scharl M;
Digestion; 2020; 101 Suppl 1():136-145. PubMed ID: 32799195
[TBL] [Abstract][Full Text] [Related]
18. Regulation of MicroRNAs in Inflammation-Associated Colorectal Cancer: A Mechanistic Approach.
Muthusami S; Ramachandran I; Krishnamoorthy S; Sambandam Y; Ramalingam S; Queimado L; Chaudhuri G; Ramachandran IK
Endocr Metab Immune Disord Drug Targets; 2021; 21(1):67-76. PubMed ID: 32940190
[TBL] [Abstract][Full Text] [Related]
19. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
[TBL] [Abstract][Full Text] [Related]
20. Chrysophanol Attenuates Manifestations of Immune Bowel Diseases by Regulation of Colorectal Cells and T Cells Activation In Vivo.
Lee HS; Jeong GS
Molecules; 2021 Mar; 26(6):. PubMed ID: 33802855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
